The Drive to Discover. The Experience to Deliver.
Incyte's vision is to become a leading drug discovery, development and commercial company by building a proprietary product pipeline of novel small molecule drugs for serious unmet medical needs.
We have experienced management, discovery, clinical development and commercial teams. Our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference in health care, improve the lives of patients and build sustainable value for our shareholders.
Our pipeline is focused on oncology and inflammation and includes compounds in various stages of development.
Our lead product, Jakafi® (ruxolitinib), a JAK1 and JAK2 inhibitor, is currently approved in the United States for the treatment of intermediate or high-risk myelofibrosis (please see Full Prescribing Information and Important Safety Information for Jakafi) and is in development as a potential treatment for other cancers.
We have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. Through strategic collaborations with Novartis and Eli Lilly, we are advancing the global development of two of our JAK1 and JAK2 inhibitor programs.
Incyte's corporate headquarters is located in Wilmington, Delaware. For more information about Incyte, please see our Corporate Fact Sheet.
- About Incyte
- Jakafi® (ruxolitinib)
- Disease Education